Table 1.
Main clinical characteristics of the included patients.
Fig 1.
Progression-free survival of patients based on (A) immunohistochemistry, (B) normal serum free light chain ratio, and (C) stringent complete response.
Fig 2.
Progression-free survival of patients with stringent complete response classified by multiparametric flow cytometry (MFC) (A) and next-generation sequencing (NGS) results (B).